|
1
|
Ohgaki H: Epidemiology of brain tumors.
Methods Mol Biol. 472:323–342. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schneider T, Mawrin C, Scherlach C, Skalej
M and Firsching R: Gliomas in adults. Dtsch Arztebl Int.
107:799–807; quiz 808. 2010.PubMed/NCBI
|
|
4
|
DeAngelis LM: Brain tumors. N Engl J Med.
344:114–123. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chamberlain MC: Temozolomide: Therapeutic
limitations in the treatment of adult high-grade gliomas. Expert
Rev Neurother. 10:1537–1544. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cancer Genome Atlas Research Network, .
Comprehensive genomic characterization defines human glioblastoma
genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shen M, Kawamoto T, Yan W, Nakamasu K,
Tamagami M, Koyano Y, Noshiro M and Kato Y: Molecular
characterization of the novel basic helix-loop-helix protein DEC1
expressed in differentiated human embryo chondrocytes. Biochem
Biophys Res Commun. 236:294–298. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Boudjelal M, Taneja R, Matsubara S,
Bouillet P, Dolle P and Chambon P: Overexpression of Stra13, a
novel retinoic acid-inducible gene of the basic helix-loop-helix
family, inhibits mesodermal and promotes neuronal differentiation
of P19 cells. Genes Dev. 11:2052–2065. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rossner MJ, Dörr J, Gass P, Schwab MH and
Nave KA: SHARPs: Mammalian enhancer-of-split- and hairy-related
proteins coupled to neuronal stimulation. Mol Cell Neurosci.
10:460–475. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bhawal UK, Sato F, Arakawa Y, Fujimoto K,
Kawamoto T, Tanimoto K, Ito Y, Sasahira T, Sakurai T, Kobayashi M,
et al: Basic helix-loop-helix transcription factor DEC1 negatively
regulates cyclin D1. J Pathol. 224:420–429. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sun H and Taneja R: Stra13 expression is
associated with growth arrest and represses transcription through
histone deacetylase (HDAC)-dependent and HDAC-independent
mechanisms. Proc Natl Acad Sci USA. 97:4058–4063. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Y, Zhang H, Xie M, Hu M, Ge S, Yang D,
Wan Y and Yan B: Abundant expression of DEC1/stra13/sharp2 in colon
carcinoma: Its antagonizing role in serum deprivation-induced
apoptosis and selective inhibition of procaspase activation.
Biochem J. 367:413–422. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thin TH, Li L, Chung TK, Sun H and Taneja
R: Stra13 is induced by genotoxic stress and regulates
ionizing-radiation-induced apoptosis. Embo Rep. 8:401–407. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ehata S, Hanyu A, Hayashi M, Aburatani H,
Kato Y, Fujime M, Saitoh M, Miyazawa K, Imamura T and Miyazono K:
Transforming growth factor-beta promotes survival of mammary
carcinoma cells through induction of antiapoptotic transcription
factor DEC1. Cancer Res. 67:9694–9703. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Y, Xie M, Yang J, Yang D, Deng R, Wan Y
and Yan B: The expression of antiapoptotic protein survivin is
transcriptionally upregulated by DEC1 primarily through multiple
sp1 binding sites in the proximal promoter. Oncogene. 25:3296–3306.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Seimiya M, Bahar R, Wang Y, Kawamura K,
Tada Y, Okada S, Hatano M, Tokuhisa T, Saisho H, Watanabe T, et al:
Clast5/Stra13 is a negative regulator of B lymphocyte activation.
Biochem Biophys Res Commun. 292:121–127. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun H, Lu B, Li RQ, Flavell RA and Taneja
R: Defective T cell activation and autoimmune disorder in
Stra13-deficient mice. Nat Immunol. 2:1040–1047. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Miyazaki K, Miyazaki M, Guo Y, Yamasaki N,
Kanno M, Honda Z, Oda H, Kawamoto H and Honda H: The role of the
basic helix-loop-helix transcription factor Dec1 in the regulatory
T cells. J Immunol. 185:7330–7339. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yun Z, Maecker HL, Johnson RS and Giaccia
AJ: Inhibition of PPAR gamma 2 gene expression by the
HIF-1-regulated gene DEC1/Stra13: A mechanism for regulation of
adipogenesis by hypoxia. Dev Cell. 2:331–341. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Iizuka K and Horikawa Y: Regulation of
lipogenesis via BHLHB2/DEC1 and ChREBP feedback looping. Biochem
Biophys Res Commun. 374:95–100. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamada K, Ogata-Kawata H, Matsuura K and
Miyamoto K: SHARP-2/Stra13/DEC1 as a potential repressor of
phosphoenolpyruvate carboxykinase gene expression. FEBS Lett.
579:1509–1514. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nakashima A, Kawamoto T, Honda KK, Ueshima
T, Noshiro M, Iwata T, Fujimoto K, Kubo H, Honma S, Yorioka N, et
al: DEC1 modulates the circadian phase of clock gene expression.
Mol Cell Biol. 28:4080–4092. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rossner MJ, Oster H, Wichert SP, Reinecke
L, Wehr MC, Reinecke J, Eichele G, Taneja R and Nave KA: Disturbed
clockwork resetting in Sharp-1 and Sharp-2 single and double mutant
mice. PLoS One. 3:e27622008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Honma S, Kawamoto T, Takagi Y, Fujimoto K,
Sato F, Noshiro M, Kato Y and Honma K: Dec1 and Dec2 are regulators
of the mammalian molecular clock. Nature. 419:841–844. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chakrabarti J, Turley H, Campo L, Han C,
Harris AL, Gatter KC and Fox SB: The transcription factor DEC1
(stra13, SHARP2) is associated with the hypoxic response and high
tumour grade in human breast cancers. Br J Cancer. 91:954–958.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zheng Y, Jia Y, Wang Y, Wang M, Li B, Shi
X, Ma X, Xiao D and Sun Y: The hypoxia-regulated transcription
factor DEC1 (Stra13, SHARP-2) and its expression in gastric cancer.
OMICS. 13:301–306. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ivanova AV, Ivanov SV,
Danilkovitch-Miagkova A and Lerman MI: Regulation of STRA13 by the
von Hippel-Lindau tumor suppressor protein, hypoxia, and the
UBC9/ubiquitin proteasome degradation pathway. J Biol Chem.
276:15306–15315. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Giatromanolaki A, Koukourakis MI, Sivridis
E, Turley H, Wykoff CC, Gatter KC and Harris AL: DEC1 (STRA13)
protein expression relates to hypoxia-inducible factor 1-alpha and
carbonic anhydrase-9 overexpression in non-small cell lung cancer.
J Pathol. 200:222–228. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang L and Li QQ: Embryo-chondrocyte
expressed gene 1, downregulating hypoxia-inducible factor 1alpha,
is another marker of lung tumor hypoxia. Acta Pharmacol Sin.
28:549–558. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shi XH, Zheng Y, Sun Q, Cui J, Liu QH, Qü
F and Wang YS: DEC1 nuclear expression: A marker of differentiation
grade in hepatocellular carcinoma. World J Gastroenterol.
17:2037–2043. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qian Y, Zhang J, Yan B and Chen X: DEC1, a
basic helix-loop-helix transcription factor and a novel target gene
of the p53 family, mediates p53-dependent premature senescence. J
Biol Chem. 283:2896–2905. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Qian Y, Jung YS and Chen X: Differentiated
embryo-chondrocyte expressed gene 1 regulates p53-dependent cell
survival versus cell death through macrophage inhibitory
cytokine-1. Proc Natl Acad Sci USA. 109:11300–11305. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sato F, Bhawal UK, Kawamoto T, Fujimoto K,
Imaizumi T, Imanaka T, Kondo J, Koyanagi S, Noshiro M, Yoshida H,
et al: Basic-helix-loop-helix (bHLH) transcription factor DEC2
negatively regulates vascular endothelial growth factor expression.
Genes Cells. 13:131–144. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ivanov SV, Salnikow K, Ivanova AV, Bai L
and Lerman MI: Hypoxic repression of STAT1 and its downstream genes
by a pVHL/HIF-1 target DEC1/STRA13. Oncogene. 26:802–812. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wykoff CC, Pugh CW, Maxwell PH, Harris AL
and Ratcliffe PJ: Identification of novel hypoxia dependent and
independent target genes of the von Hippel-Lindau (VHL) tumour
suppressor by mRNA differential expression profiling. Oncogene.
19:6297–6305. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ivanova AV, Ivanov SV, Zhang X, Ivanov VN,
Timofeeva OA and Lerman MI: STRA13 interacts with STAT3 and
modulates transcription of STAT3-dependent targets. J Mol Biol.
340:641–653. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang W, Reiser-Erkan C, Michalski CW,
Raggi MC, Quan L, Yupei Z, Friess H, Erkan M and Kleeff J: Hypoxia
inducible BHLHB2 is a novel and independent prognostic marker in
pancreatic ductal adenocarcinoma. Biochem Biophys Res Commun.
401:422–428. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Meyer SE, Hasenstein JR, Baktula A, Velu
CS, Xu Y, Wan H, Whitsett JA, Gilks CB and Grimes HL: Kruppel-like
factor 5 is not required for K-RasG12D lung tumorigenesis, but
represses ABCG2 expression and is associated with better
disease-specific survival. Am J Pathol. 177:1503–1513. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Soon MS, Hsu LS, Chen CJ, Chu PY, Liou JH,
Lin SH, Hsu JD and Yeh KT: Expression of Krűppel-like factor 5 in
gastric cancer and its clinical correlation in Taiwan. Virchows
Arch. 459:161–166. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pazo CR and Antón A: Advanced
HER2-positive gastric cancer: Current and future targeted
therapies. Crit Rev Oncol Hematol. 85:350–362. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nakamura H, Tanimoto K, Hiyama K, Yunokawa
M, Kawamoto T, Kato Y, Yoshiga K, Poellinger L, Hiyama E and
Nishiyama M: Human mismatch repair gene, MLH1, is transcriptionally
repressed by the hypoxia-inducible transcription factors, DEC1 and
DEC2. Oncogene. 27:4200–4209. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sarkaria JN, Kitange GJ, James CD, Plummer
R, Calvert H, Weller M and Wick W: Mechanisms of chemoresistance to
alkylating agents in malignant glioma. Clin Cancer Res.
14:2900–2908. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Taverna P, Liu L, Hanson AJ, Monks A and
Gerson SL: Characterization of MLH1 and MSH2 DNA mismatch repair
proteins in cell lines of the NCI anticancer drug screen. Cancer
Chemother Pharmacol. 46:507–516. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu L, Markowitz S and Gerson SL: Mismatch
repair mutations override alkyltransferase in conferring resistance
to temozolomide but not to 1,3-bis (2-chloroethyl) nitrosourea.
Cancer Res. 56:5375–5379. 1996.PubMed/NCBI
|
|
47
|
Hickman MJ and Samson LD: Role of DNA
mismatch repair and p53 in signaling induction of apoptosis by
alkylating agents. Proc Natl Acad Sci USA. 96:10764–10769. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Turley H, Wykoff CC, Troup S, Watson PH,
Gatter KC and Harris AL: The hypoxia-regulated transcription factor
DEC1 (Stra13, SHARP-2) and its expression in human tissues and
tumours. J Pathol. 203:808–813. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ali SS, Hsiao M, Zhao HW, Dugan LL, Haddad
GG and Zhou D: Hypoxia-adaptation involves mitochondrial metabolic
depression and decreased ROS leakage. PLoS One. 7:e368012012.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Oliva CR, Moellering DR, Gillespie GY and
Griguer CE: Acquisition of chemoresistance in gliomas is associated
with increased mitochondrial coupling and decreased ROS production.
PLoS One. 6:e246652011. View Article : Google Scholar : PubMed/NCBI
|
